CEOs are great talkers, they tell you what you want to hear. Thinking that DX1 manufacturing success will lead to bringing in non dilutive cash for DX3 is so incredibly wishful.
Also I’m not usually one to correct grammar but is there a reason you‘ve been spelling sporadic wrong for the last 12 months? Am I missing something?
Ann: Presentation to highlight broader potential of Deoxymabs, page-67
-
- There are more pages in this discussion • 23 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PAB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.8¢ |
Change
0.001(14.3%) |
Mkt cap ! $16.46M | |||
| Open | High | Low | Value | Volume |
| 0.7¢ | 0.8¢ | 0.7¢ | $2.916K | 398.9K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 12 | 3479285 | 0.7¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.8¢ | 1732079 | 8 |
View Market Depth
| Last trade - 16.10pm 20/06/2024 (20 minute delay) ? |
| PAB (ASX) Chart |